Eva Dahlén, Ph.D., is Director, Search & Evaluation, at Novo Nordisk. In this capacity, she leads innovation sourcing activities across a range of technology areas, including RNA & gene therapy, oral and alternative delivery of biologics, and AI/ML-enabled target and drug discovery, applicable in cardiometabolic and rare diseases. With > 20 years experience in the life science sector, Eva has held various positions in BD and R&D, most recently as senior director business development at Alligator Bioscience, and prior roles including principal scientist and project and team leader positions for discovery and development of immunotherapeutic drugs.
Eva has a scientific background in immunology and oncology. She holds a Ph.D. in immunology from Lund university, Sweden, and has conducted research in basic immunology, inflammation and immuno-oncology.